论文部分内容阅读
目的探讨伊立替康联合顺铂在小细胞肺癌治疗中的临床疗效和毒副反应。方法选取本院肿瘤科2011年6月~2012年12月采用伊立替康联合顺铂方案(IP)治疗小细胞肺癌的患者33例,回顾性分析其临床疗效和毒副反应,并同本院肿瘤科同一时期内采用依托泊苷联合顺铂方案(EP)治疗的小细胞肺癌患者32例进行对比分析。结果 IP组客观缓解率(OR)为66.67%,EP组客观缓解率为(OR)为65.63%,两组OR比较,差异无统计学意义(P>0.05);两组常见的毒副反应为骨髓抑制、消化道症状(恶心呕吐、腹泻)和血液学毒性,IP组白细胞和血小板减少发生率低于EP组(P<0.05),而消化道症状发生率高于EP组(P<0.05)。两组均未发生毒性相关死亡病例。结论伊立替康联合顺铂方案临床疗效高、毒副反应较低,值得作为小细胞肺癌的治疗方案进行临床推广。
Objective To investigate the clinical efficacy and toxicity of irinotecan combined with cisplatin in the treatment of small cell lung cancer. Methods Thirty-three patients with small-cell lung cancer treated with irinotecan plus cisplatin (IP) were selected from June 2011 to December 2012 in our department of oncology. The clinical efficacy and toxicity were retrospectively analyzed. 32 patients with small cell lung cancer treated with etoposide combined with cisplatin (EP) during the same period of oncology were compared and analyzed. Results The objective response rate (OR) was 66.67% in the IP group and 65.63% in the EP group. There was no significant difference in OR between the two groups (P> 0.05). The common adverse reactions in both groups were Myelosuppression, gastrointestinal symptoms (nausea and vomiting, diarrhea) and hematological toxicity. The incidence of white blood cells and thrombocytopenia in IP group was lower than that in EP group (P <0.05), while the incidence of gastrointestinal symptoms was higher than that in EP group (P <0.05) . No toxic-related deaths occurred in either group. Conclusion The combination of irinotecan and cisplatin has high curative effect and low toxic and side effects. It is worth to be used as a clinical treatment for small cell lung cancer.